We demonstrate that a novel, peripherally restricted CB1R antagonist, JD5037, is effective in reversing obesity and its deleterious metabolic effects in DIO Magel2-null mice, which exhibit fundamental aspects of the PWS phenotype [22]. Here, CNR1 is linked to obesity disorder.